Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Results from largest randomized TAVR trial to date presented at TCT 2022
News | Embolic Protection Devices
Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL Cerebral Protection System

September 17, 2022 —  Boston Scientific Corporation has announced results from the PROTECTED TAVR clinical trial ...

Home September 17, 2022
Home
Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).
News | TCT
Edwards Pascal Precision Transcatheter Valve Repair System Receives FDA Approval for Degenerative Mitral Regurgitation

September 16, 2022 — Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter ...

Home September 16, 2022
Home
Results from Largest Ever Real-World Evaluation of the MANTA Device Demonstrated Safety and Effectiveness with Low Complication Rates and a Short Learning Curve
News | Vascular Closure Devices
Co-Author of the Karolinska 1000 Consecutive MANTA Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

September 16, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced that Dr. Magnus ...

Home September 16, 2022
Home
RECOVER IV is an on-label, two arm RCT that is designed to provide the clinical evidence needed to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock.
News | Cardiogenic Shock
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

September 16, 2022 — Abiomed announced two approvals from the U.S. Food and Drug Administration (FDA) related to ...

Home September 16, 2022
Home
Global consensus data recommends the use of intravascular ultrasound (IVUS) in many peripheral vascular disease (PVD) procedures
News | TCT
Philips Showcases Clinical Data and Solutions Designed to Deliver Better Cardiac Care with Greater Efficiency at TCT 2022

September 15, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its ...

Home September 15, 2022
Home
Findings reveal AFib patients are fearful of complications from the condition, but not all are treating their AFib quicky after diagnosis
News | Atrial Fibrillation
Biosense Webster AFib Survey Findings Reveal Surprising Patient Behaviors and At-Risk Population Awareness Gaps

September 14, 2022 — In recognition of Atrial Fibrillation (AFib) Awareness Month, Biosense Webster, Inc., part of ...

Home September 14, 2022
Home
Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA (Vascular InterVentional Advances) Annual Conference, Oct. 30-Nov. 3, 2022, have been announced.
News | Cardiovascular Education
Late-breaking Clinical Trial presentations announced for The VEINS and VIVA Conference

September 14, 2022 — Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INte ...

Home September 14, 2022
Home
Anthos Therapeutics has announced that Abelacimab has received FDA Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
News | Stroke
Anthos Therapeutics Announces Abelacimab Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with AFib

September 13, 2022 — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for ...

Home September 13, 2022
Home
TherOx Console
News | STEMI
First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients

September 13, 2022 — ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related ...

Home September 13, 2022
Home
DAIC editors outline some highlights of what to expect from this year’s conference.
Feature | TCT | By Melinda Taschetta-Millane
Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference Preview

The Transcatheter Cardiovascular Therapeutics (TCT) conference, which is the Cardiovascular Research Foundation's (CRF) ...

Home September 12, 2022
Home
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation
News | Left Atrial Appendage (LAA) Occluders
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option

September 12, 2022 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to ...

Home September 12, 2022
Home
Results from ENVISAGE-TAVI AF show mortality risk score for AFib patients undergoing TAVR. Image courtesy of Mount Sinai Health System
News | Atrial Fibrillation
New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement

September 9, 2 022 — A large-scale international study led by Mount Sinai has yielded the first risk score that can help ...

Home September 09, 2022
Home
investigator Michelle O’Donoghue, MD, MPH, a senior investigator of the TIMI Study Group in the Division of Cardiovascular Medicine. Image courtesy of Michelle O'Donoghue/Brigham and Women's Hospital
News | Cardiovascular Clinical Studies
FOURIER-OLE Trial Finds that Long-term Use of Evolocumab Further Reduced Cardiovascular Events

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
Top 10 content for the month of August 2022
Feature | Cardiovascular Business | By Melinda Taschetta-Millane
Top 10: A Look at the Hot Topics from August

Here is a rundown of what you and your colleagues found to be most interesting in the fields of diagnostic and ...

Home September 07, 2022
Home
Prespecified meta-analysis of DELIVER and EMPEROR-Preserved presented in a Hot Line Session at ESC Congress 2022
News | Pharmaceuticals
Meta-Analysis Strengthens Evidence for SGLT2 Inhibitors in Patients With Heart Failure

September 6, 2022 — An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empag ...

Home September 06, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now